Portola Pharmaceuticals
American clinical stage biotechnology company / From Wikipedia, the free encyclopedia
Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies.[2] Founded in 2003 and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index.
Quick Facts Company type, Traded as ...
Company type | Public[1] |
---|---|
| |
Industry | Pharmaceuticals |
Founded | 2003 |
Founders | Charles J. Homcy, David R. Philips |
Fate | Acquired by Alexion Pharmaceuticals |
Headquarters | South San Francisco, California, United States |
Area served | Worldwide |
Key people | Scott Garland (CEO)[1] |
Products | Andexxa Bevyxxa Cerdulatinib |
Revenue | $40,130 (2018)[1] |
Number of employees | 324 (2018)[1] |
Subsidiaries | Portola Pharma UK Limited |
Website | portola |
Close
In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola.[3]